BETA


2008/0255(COD) Medicinal products for human use: information on products subject to medical prescription

Progress: Procedure lapsed or withdrawn

RoleCommitteeRapporteurShadows
Lead ENVI FJELLNER Christofer (icon: PPE PPE) PARGNEAUX Gilles (icon: S&D S&D), CHATZIMARKAKIS Jorgo (icon: ALDE ALDE), SCHLYTER Carl (icon: Verts/ALE Verts/ALE), YANNAKOUDAKIS Marina (icon: ECR ECR), ROSBACH Anna (icon: EFD EFD)
Former Responsible Committee ENVI
Former Responsible Committee ENVI FJELLNER Christofer (icon: PPE PPE)
Committee Opinion ITRE CHATZIMARKAKIS Jorgo (icon: ALDE ALDE)
Committee Opinion IMCO CORREIA DE CAMPOS António Fernando (icon: S&D S&D)
Former Committee Opinion ITRE
Former Committee Opinion IMCO
Former Committee Opinion ITRE
Former Committee Opinion IMCO Ashley FOX (icon: ECR ECR), Matteo SALVINI (icon: ENF ENF)
Lead committee dossier:
Legal Basis:
TFEU 114-p1, TFEU 168-p4

Events

2014/05/21
   EC - Proposal withdrawn by Commission
Details

As announced in Official Journal C 153 of 21 May 2014, the Commission decided to withdraw this proposal, which had become obsolete.

2012/04/24
   LU_CHAMBER - Contribution
Documents
2012/04/11
   IT_SENATE - Contribution
Documents
2012/04/11
   PT_PARLIAMENT - Contribution
Documents
2012/03/28
   ESC - Economic and Social Committee: opinion, report
Documents
2012/03/01
   EP - FJELLNER Christofer (PPE) appointed as rapporteur in ENVI
2012/02/22
   ESC - Economic and Social Committee: opinion, report
Documents
2012/02/10
   EP/CSL - Formal reconsultation of Parliament
2012/02/10
   EC - Amended legislative proposal for reconsultation published
Details

The Commission presents, for re-consultation , an amended proposal for a Regulation of the European Parliament and the Council on information to the general public on medicinal products subject to medical prescription. The amended proposal incorporates the amendments proposed by the European Parliament at first reading on 24 November 2010 as the Commission considers them acceptable.

The general policy objectives of the proposals to amend Directive 2001/83/EC and Regulation (EC) No 726/2004 are in line with the overall objectives of the EU pharmaceutical legislation. This amended proposal is in line with those objectives to include measures setting high standards of safety for medicinal products. Therefore, in view of the entry into force of the Treaty of Lisbon since the adoption of the Commission proposal, article 168(4) of the Treaty on the Functioning of the European Union is added as legal basis to the amended proposal.

Moreover, this amended proposal further reinforces the rights of patients. In particular, the marketing authorisation holders will have the obligation , and no longer the possibility, to make available certain information, such as the labelling and the package leaflet.

The amendments introduced by the Commission in light of the European Parliament’s amendments aim to :

recall that in the Commission Communication concerning the " Report on current practices with regard to the provision of information to patients on medicinal products " the need for a more precise distinction between advertising and information was highlighted ; specify that the new Title introduced in Directive 2001/83/EC is intended to place emphasis on the rights and interests of patients; specify that although the pre-control of information is performed by the Agency for centrally approved medicinal products, the monitoring of the information rests with Member States. It is appropriate to ensure consistently that the Agency is also responsible for the control of the information made available through Internet websites registered in the Member States. Specific provisions are introduced to clarify the operation of this control mechanism in such case of information made available through Internet websites registered with the Member States; provide for the procedure regarding cases when the Agency requests for changes within the information submitted for control and for the fees applicable which should be proportionate to the additional work. Considering that the normal delay is 60 days, the subsequent delay should be of 30 days; provide that the EudraPharm database should be available in all EU languages . Such a change has been introduced as regards the lay-out of the database; on the other hand, the information contained in the database will be available in the languages of Member States where the medicinal product is authorised; provide that EudraPharm should be actively promoted to European citizens . This should be done through the development of the European medicines web-portal established by Regulation (EU) No 1235/2010 as the central point of access to information about medicinal products.

The proposal has no implication for the budget of the Union.

For legal clarity and in order to facilitate the ordinary legislative procedure, this text replaces COM(2011) 632 final , presented on 11/10/2011, which is consequently withdrawn.

2011/10/11
   EC - Modified legislative proposal published
Details

The Commission presents an amended proposal for a Regulation of the European Parliament and of the Council on information to the general public on medicinal products subject to medical prescription. Incorporated within the amended proposal are amendments proposed by the European Parliament at its first reading which are acceptable to the Commission.

12 amendments on the proposal were adopted by Parliament at first reading . The Commission considers that a majority of Parliament's amendments are acceptable in full, in principle, or in part, as they maintain the aims and overall scheme of the proposal.

The Commission therefore incorporates in full or in part, the following amendments of the European Parliament in the amended proposal:

it underlines that in the Commission Communication transmitted on 20 December 2007 concerning the "Report on current practices with regard to the provision of information to patients on medicinal products" the need for a more precise distinction between advertising and information was highlighted; it is specified that the new Title introduced in Directive 2001/83/EC is intended to place emphasis on the rights and interests of patients. It also states that although the pre-control of information is performed by the Agency for centrally approved medicinal products, the monitoring of the information rests with Member States. It is appropriate to ensure consistently that the Agency is also responsible for the control of the information made available through Internet websites registered in the Member States. Specific provisions are introduced to clarify the operation of this control mechanism in such case of information made available through Internet websites registered with the Member States. The Commission acknowledges that a number of Member States have expressed concerns regarding conformity with their national constitutions. The Commission is prepared to enter into a dialogue with those concerned to find suitable solutions while fully respecting the objectives of this Regulation; it provides for the procedure regarding cases when the Agency requests changes within the information submitted for control and for the fees applicable which should be proportionate to the additional work. Considering that the normal delay is 60 days, the subsequent delay should be of 30 days; the text provides that the EudraPharm database it should be available in all EU languages. Such a change has been introduced as regards the lay-out of the database. However, the information contained in the database will be available in the languages of Member States where the medicinal product is authorised. In another respect, it is not necessary to further specify that the information provided is designed for non-experts, as it is already provided that it should be worded in an appropriate and comprehensible manner. EudraPharm should be actively promoted to European citizens. This should be done through the development of the European medicines web-portal established by Regulation (EU) No 1235/2010 as the central point of access to information about medicinal products. However, it is not appropriate that information available on marketing authorisation holder websites is reproduced on EudraPharm, which is a public database.

Pharmacovigilance: in addition to the changes introduced on the basis of the European Parliament resolutions regarding the Commission proposals on information to patients, the Commission considers that limited changes to Regulation (EC) No 726/2004 in the area of pharmacovigilance should be introduced. Regulation (EC) No 726/2004 has been recently amended by Regulation (EU) No 1235/2010 to revise the EU pharmacovigilance system. Since Regulation (EU) No 1235/2010 has as legal basis Article 168(4)(c) of TFUE, the amended proposal should also be based on Article 168(4)(c) of TFUE .

Regulation (EU) No 1235/2010 substantially strengthens the legal framework for the surveillance of medicinal products in the EU. However, in view of recent pharmacovigilance events in the EU, the Commission has detected certain areas where the legislation could be further strengthened.

Therefore:

the new public list of medicinal products subject to additional monitoring introduced by Regulation (EU) No 1235/2010 will not necessarily include all medicinal products subject to post-authorisation safety conditions. Competent authorities will have to decide on a case-by-case basis whether to make public the fact that products are subject to strengthened surveillance. For the sake of fuller transparency as regards products under special surveillance, the text is modified to systematically include medicinal products that are subject to conditions and requirements with regard to safety; a new provision is introduced to avoid a situation where the voluntary withdrawal of a marketing authorisation or product by the holder could lead to safety issues not being addressed in the EU. It clarifies the information obligations of the marketing authorisation holder.

Lastly, the text clarifies the scope of this provision and the EU procedures set out in Directive 2001/83/EC.

2011/05/30
   CSL - Debate in Council
Documents
2011/05/30
   CSL - Council Meeting
2011/01/26
   EC - Commission response to text adopted in plenary
Documents
2010/12/06
   CSL - Debate in Council
Details

The Commission expressed its willingness to modify its proposal concerning information to the general public on medicinal products for human use which are subject to prescription in order to take into account the concerns of the Member States.

The incoming Hungarian Presidency announced its willingness to address this file as a matter of priority as soon as the modified proposal has been presented.

Documents
2010/12/06
   CSL - Council Meeting
2010/11/24
   EP - Results of vote in Parliament
2010/11/24
   EP - Decision by Parliament, 1st reading
Details

The European Parliament adopted by 564 votes to 41, with 45 abstentions, a legislative resolution on the proposal for a regulation of the European Parliament and of the Council on amending, as regards information to the general public on medicinal products for human use subject to medical prescription, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency.

It adopted its position at first reading under the ordinary legislative procedure (formerly known as the codecision procedure) in which it amends the Commission proposal as follows:

Patients’ rights : Parliament considers that the Amending Directive has to focus on the patients and their interests and it has to be reflected in the Amending Regulation as well. The new provisions of the Amending Directive have to emphasise the right of patients for information instead of the right of the pharmaceutical companies to disseminate information.

Information : the resolution highlights the urgent need for a more precise distinction between advertising and information.

Non-promotional information on medicinal products must be made available to patients and to the general public by marketing authorisation holders according to the "pull principle" whereby patients/the public have access to information if they need it (contrary to the "push principle" whereby the marketing authorisation holders disseminate information among the patients and the general public).

In this context, Parliament proposes an amendment relating to information not approved by competent authorities during the registration of medicinal products and is in fact hidden “push” information. Any relevant information relating to studies is included in the patient leaflet and the Summary of Product Characteristics (SmPC), which is part of the registration file for approval.

Time-limit for information : The Agency may object to the information submitted or parts thereof on grounds related to non-compliance with the provisions of Title VIIIa of Directive 2001/83/EC within 90 days (instead of 60 days) after receipt of the notification. If the Agency does not object within 90 days, the information shall be deemed accepted and may be published. The marketing authorisation holder shall remain fully liable and responsible for the information provided in all cases.

If the Agency asks for changes to be made to a document submitted by the marketing authorisation holder, and if the latter resubmits an improved proposal within 30 working days, the Agency shall communicate its response to the new proposal within 60 working days.

Database on medicinal products : the resolution underlines that strengthening the EMEA’s role with regard to information for the public on medicinal products for which a medical prescription is required is crucial in order to ensure that all citizens have equal access to high-quality information. The management of the database of information for the public should comply with exemption criteria for that information.

The database on medicinal products should be accessible to the general public, in all official languages of the Union and should be managed independently of the commercial interests of pharmaceutical companies. It should be publicly accessible as a prime source of objective information. With this aim in mind, the Member States, the Commission and the Agency itself should make every effort to ensure that proper use is made of this database.

Members insist on promoting existing sources of independent reliable health information. There are many sources of independent and evidence-based information on treatment choices available within the European Union. These resources take into account cultural specificities and contexts for the population, including health determinants. They are developed by health authorities, medical products agencies, healthcare assessment bodies, healthcare providers, healthcare professionals, consumer organisations, and independent patients’ organisations. These information sources should be actively promoted to the general public.

Agency’s budget : the resolution requests that in the event that the additional costs incurred by the Agency as a result of its preliminary checking of certain types of information pursuant to this Regulation are not covered by the fees payable by the marketing authorisation holders for this purpose, the amount of the European Union’s contribution to the Agency’s budget should be reviewed. Accordingly, efforts should be initiated at Member State level with a view to the possible amendment of the European Union’s contribution to the Agency.

Documents
2010/11/22
   EP - Debate in Parliament
2010/10/19
   EP - Committee report tabled for plenary, 1st reading/single reading
Documents
2010/10/19
   EP - Committee report tabled for plenary, 1st reading
Documents
2010/09/28
   EP - Vote in committee, 1st reading
Details

The Committee on the Environment, Public Health and Food Safety adopted the report drafted by Christofer FJELLNER (EPP, SE) on the proposal for a regulation of the European Parliament and of the Council on amending, as regards information to the general public on medicinal products for human use subject to medical prescription, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency.

The committee recommended that the European Parliament’s position at first reading under the ordinary legislative procedure (formerly known as the codecision procedure) should be to amend the Commission proposal as follows:

Patients’ rights : Members consider that the Amending Directive has to focus on the patients and their interests and it has to be reflected in the Amending Regulation as well. The new provisions of the Amending Directive have to emphasise the right of patients for information instead of the right of the pharmaceutical companies to disseminate information.

Information : the report highlights the urgent need for a more precise distinction between advertising and information .

Non-promotional information on medicinal products must be made available to patients and to the general public by marketing authorisation holders according to the "pull principle" whereby patients/the public have access to information if they need it (contrary to the "push principle" whereby the marketing authorisation holders disseminate information among the patients and the general public).

In this context, Members propose an amendment relating to information not approved by competent authorities during the registration of medicinal products and is in fact hidden “push” information. Any relevant information relating to studies is included in the patient leaflet and the Summary of Product Characteristics (SmPC), which is part of the registration file for approval.

Extending the time-limit for information : Members propose extending the timeline for the tacit acceptance of the information from 60 to 120 days in order to meet the organisational needs of the Agency and to ensure that the companies remain fully liable for the information they provide to the general public. If the Agency asks for changes to a document submitted by the marketing authorisation holder, and if the latter resubmits an improved proposal within 30 working days, the Agency shall communicate its response to the new proposal within 60 working days.

Database on medicinal products : the report underlines that strengthening the EMEA’s role with regard to information for the public on medicinal products for which a medical prescription is required is crucial in order to ensure that all citizens have equal access to high-quality information. The management of the database of information for the public should comply with exemption criteria for that information.

The database should be publicly accessible as a prime source of objective information. With this aim in mind, the Member States, the Commission and the Agency itself should make every effort to ensure that proper use is made of this database.

Members insist on promoting existing sources of independent reliable health information. There are many sources of independent and evidence-based information on treatment choices available within the European Union. These resources take into account cultural specificities and contexts for the population, including health determinants. They are developed by health authorities, medical products agencies, healthcare assessment bodies, healthcare providers, healthcare professionals, consumer organisations, and independent patients’ organisations. These information sources should be actively promoted to the general public.

Agency’s budget : the report requests that in the event that the additional costs incurred by the Agency as a result of its preliminary checking of certain types of information pursuant to this Regulation are not covered by the fees payable by the marketing authorisation holders for this purpose, the amount of the European Union’s contribution to the Agency’s budget should be reviewed. Accordingly, efforts should be initiated at Member State level with a view to the possible amendment of the European Union’s contribution to the Agency.

2010/05/04
   EP - Amendments tabled in committee
Documents
2010/04/30
   EP - Committee opinion
Documents
2010/03/24
   EP - Committee opinion
Documents
2010/03/10
   EP - Committee draft report
Documents
2009/11/30
   CSL - Debate in Council
Details

On the basis of progress reports, the Presidency informed the Council of the state of play in the negotiations on two parts of the "pharmaceutical package": preventing falsified medicines from entering into the legal supply chain of medicinal products and the strengthening and rationalising of the current pharmacovigilance system.

Under the Swedish Presidency, the preparatory bodies of the Council pursued their work with high priority on these two parts of the package.

1) Concerning the draft directive on preventing the entry into the legal supply chain of falsified medicinal products , the working group reached tentative agreement on a number of technical aspects, including:

· the definition of "falsified medicinal products";

· the proposed definition of ''trading of medicinal products'' has been changed to ''brokering of medicinal products'' and amended, thereby clarifying which actors in the supply chain should be subject to the responsibilities of brokers. The proposed introduction of obligations for brokers aim to reinforce the traceability of medicinal products;

· a clarification of the relationship between the proposed new provisions in Directive 2001/83/EC and Community legislation on intellectual property rights.

Other elements of the proposal still need further discussion, notably with regard to the strengthening of controls of non active substances used in pharmaceuticals (excipients) and the proposed safety features aiming to render falsification more difficult.

The proposal includes provisions requiring the accreditation of third party auditors of Good Manufacturing Practices and Good Distribution Practices. A majority of delegations object to accreditation, since they maintain that such a system could result in a transfer of responsibility from manufacturers and importers as well as make enforcement by national competent authorities more difficult. The Presidency has therefore proposed to delete the provisions regarding accreditation from the text. Some delegations have expressed an interest in the possibility of establishing third party accreditation at a national level.

2) Concerning the proposals for a regulation and a directive on strengthening the EU system for the safety monitoring of medicinal products ("pharmacovigilance"), the working group reached tentative agreement on a number of questions including:

· a clarification of the relation between the proposed new provisions in Directive 2001/83/EC and Regulation (EC) 726/2004 on the one hand and the Community legislation on protection of personal data on the other hand;

· a strengthening of the role of the Pharmacovigilance Risk Assessment Committee (PRAC) in relation to the Committee for Medicinal Products for Human Use and to the Coordination Group set up by Article 27 of Directive 2001/83/EC (CMD), including an obligation for these last two bodies to explain any differences in opinion compared to the PRAC;

· a change in the composition of the PRAC and in the method for nominating the PRAC members so that all Member States will be represented;

· the inclusion of a requirement for the Agency, in collaboration with the Member States and the Commission, to draw up functional specifications for the Eudravigilance database which will take account of the role and experience of national competent authorities for pharmacovigilance. The new reporting obligations to Eudravigilance will not apply until these specifications are met and to this end a transitional period is envisaged;

· the legal status of CMD opinions and how they are implemented in Member States. Here, text redrafting proposals are under legal scrutiny.

The Working Party has continued to discuss other central provisions of the proposals, mainly in relation to the Community Procedure and Referrals, the Recording and Reporting of adverse reactions, the Periodic Safety Update Reports and the Post Authorisation Safety Studies.

A number of issues still require further examination, such as the recording and reporting of adverse reactions and the proposed list of medicinal products for human use under intensive monitoring.

At this stage, all delegations have a general scrutiny reservation on the entire proposal while the Danish, Maltese and United Kingdom delegations have parliamentary scrutiny reservations.

3) With regard to the third part of the "pharmaceutical package", the proposals for a regulation and a directive concerning information for the general public on medicinal products, the Presidency recalled the strong concerns of many Member States. The Commission made it clear that it is prepared to show flexibility in order to find a common basis for the future negotiations.

Documents
2009/11/30
   CSL - Council Meeting
2009/10/19
   EP - Committee referral announced in Parliament, 1st reading
2009/09/16
   EP - CHATZIMARKAKIS Jorgo (ALDE) appointed as rapporteur in ITRE
2009/09/14
   EP - CORREIA DE CAMPOS António Fernando (S&D) appointed as rapporteur in IMCO
2009/07/21
   EP - FJELLNER Christofer (PPE) appointed as rapporteur in ENVI
2009/06/10
   ESC - Economic and Social Committee: opinion, report
Documents
2009/01/13
   EP - Committee referral announced in Parliament, 1st reading
2008/12/10
   EC - Legislative proposal
Details

PURPOSE: to promote public health in the Community by establishing harmonised rules on the provision of information on medicinal products subject to medical prescription.

PROPOSED ACT: Directive of the European Parliament and of the Council.

BACKGROUND: Directive 2001/83/EC on the Community code relating to medicinal products for human use provides for a harmonised framework on advertising of medicines at Community level, the application of which remains a responsibility of Member States. This legislation prohibits the advertising to the general public of medicines subject to prescription.

However, neither the Directive nor Regulation (EC) No 726/2004 include detailed provisions on information on medicinal products, providing only that certain information supply activities are exempted from the advertising provisions. Therefore, Community legislation does not prevent Member States from establishing their own approaches regarding the provision of information on medicinal products as long as the above mentioned rules on advertising are respected. In addition, the boundaries between advertising and information, and therefore the field of application of the legislation's restrictions on advertising, are not interpreted consistently across the Community.

Pursuant to Directive 2001/83/EC, a Communication from the Commission to the European Parliament and the Council concerning the "Report on current practices with regard to the provision of information to patients on medicinal products" (see COD/1999/0134 under “ Follow-up documents ”) was adopted and submitted to the European Parliament and the Council on 20 December 2007. According to the Report, rules and practices on what information can be made available vary significantly among Member States. Moreover, divergences in terms of rules and practices on what information can be made available have a negative impact on legal certainty for marketing authorisation holders with cross-border activity.

CONTENT: the Commission proposes to amend Directive 2001/83/EC and Regulation (EC) No 726/2004 (see also COD/2008/0256 ) to address the gap in the current pharmaceutical legislation as regards the provision of information to the general public on prescription-only medicinal product for human use. The aim is to enhance the rational use of these medicines, while ensuring that the legislative framework continues to prohibit direct-to-consumer advertising of prescription-only medicines.

The main elements of the proposals can be summarised as follows:

clarifying that the provision of information on prescription-only medicines directly to the public by marketing authorisation holders is allowed, without prejudice to the prohibition on advertising, provided that clearly defined conditions are fulfilled; establishing harmonised conditions on the content of information which marketing authorisation holders are allowed to disseminate (information approved by the competent authorities for granting marketing authorisation, whether used literally or presented in a different way, and other limited medicine-related information); establishing harmonised quality standards for such information, to ensure that it is of high-quality and non-promotional; determining the authorised channels of information provision , in order to exclude unsolicited means of dissemination; introducing the obligation for Member States to establish a monitoring system to ensure that the abovementioned provisions on content of information, quality standards and dissemination channels are complied with and ensure enforcement in case of non-compliance. The proposal leaves it up to the Member States to decide the most appropriate monitoring mechanisms, but lays down a general rule that monitoring should take place after dissemination of information, with certain exceptions (where prior approval would be necessary) in the case of certain modalities of information where the distinction between advertising and non-promotional information is more difficult to establish. For products authorised in accordance with Regulation (EC) No 726/2004, certain approval tasks are given to the European Medicines Agency;

establishing specific monitoring rules for information disseminated through websites , to take account of the cross-border nature of information provided over the Internet and to allow Member State cooperation and avoid duplication of monitoring.

2008/12/10
   EC - Document attached to the procedure
2008/12/10
   EC - Document attached to the procedure
2008/12/09
   EC - Legislative proposal published
Details

PURPOSE: to promote public health in the Community by establishing harmonised rules on the provision of information on medicinal products subject to medical prescription.

PROPOSED ACT: Directive of the European Parliament and of the Council.

BACKGROUND: Directive 2001/83/EC on the Community code relating to medicinal products for human use provides for a harmonised framework on advertising of medicines at Community level, the application of which remains a responsibility of Member States. This legislation prohibits the advertising to the general public of medicines subject to prescription.

However, neither the Directive nor Regulation (EC) No 726/2004 include detailed provisions on information on medicinal products, providing only that certain information supply activities are exempted from the advertising provisions. Therefore, Community legislation does not prevent Member States from establishing their own approaches regarding the provision of information on medicinal products as long as the above mentioned rules on advertising are respected. In addition, the boundaries between advertising and information, and therefore the field of application of the legislation's restrictions on advertising, are not interpreted consistently across the Community.

Pursuant to Directive 2001/83/EC, a Communication from the Commission to the European Parliament and the Council concerning the "Report on current practices with regard to the provision of information to patients on medicinal products" (see COD/1999/0134 under “ Follow-up documents ”) was adopted and submitted to the European Parliament and the Council on 20 December 2007. According to the Report, rules and practices on what information can be made available vary significantly among Member States. Moreover, divergences in terms of rules and practices on what information can be made available have a negative impact on legal certainty for marketing authorisation holders with cross-border activity.

CONTENT: the Commission proposes to amend Directive 2001/83/EC and Regulation (EC) No 726/2004 (see also COD/2008/0256 ) to address the gap in the current pharmaceutical legislation as regards the provision of information to the general public on prescription-only medicinal product for human use. The aim is to enhance the rational use of these medicines, while ensuring that the legislative framework continues to prohibit direct-to-consumer advertising of prescription-only medicines.

The main elements of the proposals can be summarised as follows:

clarifying that the provision of information on prescription-only medicines directly to the public by marketing authorisation holders is allowed, without prejudice to the prohibition on advertising, provided that clearly defined conditions are fulfilled; establishing harmonised conditions on the content of information which marketing authorisation holders are allowed to disseminate (information approved by the competent authorities for granting marketing authorisation, whether used literally or presented in a different way, and other limited medicine-related information); establishing harmonised quality standards for such information, to ensure that it is of high-quality and non-promotional; determining the authorised channels of information provision , in order to exclude unsolicited means of dissemination; introducing the obligation for Member States to establish a monitoring system to ensure that the abovementioned provisions on content of information, quality standards and dissemination channels are complied with and ensure enforcement in case of non-compliance. The proposal leaves it up to the Member States to decide the most appropriate monitoring mechanisms, but lays down a general rule that monitoring should take place after dissemination of information, with certain exceptions (where prior approval would be necessary) in the case of certain modalities of information where the distinction between advertising and non-promotional information is more difficult to establish. For products authorised in accordance with Regulation (EC) No 726/2004, certain approval tasks are given to the European Medicines Agency;

establishing specific monitoring rules for information disseminated through websites , to take account of the cross-border nature of information provided over the Internet and to allow Member State cooperation and avoid duplication of monitoring.

Documents

Activities

Votes

Rapport Fjellner A7-0289/2010 - Résolution législative #

2010/11/24 Outcome: +: 564, 0: 45, -: 41
DE IT GB ES PL RO FR HU NL AT PT BG BE SE CZ FI SK IE LT LV LU CY EE MT SI DK EL
Total
90
54
60
46
41
31
64
20
20
17
21
15
21
15
22
12
12
11
9
8
6
6
5
5
5
12
21
icon: PPE PPE
244

Czechia PPE

2

Luxembourg PPE

3
2

Estonia PPE

For (1)

1

Malta PPE

2

Slovenia PPE

For (1)

1

Denmark PPE

Abstain (1)

1
icon: S&D S&D
176

Netherlands S&D

3
3

Finland S&D

2

Latvia S&D

1

Luxembourg S&D

For (1)

1

Estonia S&D

For (1)

1

Slovenia S&D

For (1)

Against (1)

2
icon: ALDE ALDE
76

Sweden ALDE

3

Lithuania ALDE

1

Latvia ALDE

For (1)

1

Luxembourg ALDE

For (1)

1

Estonia ALDE

2

Slovenia ALDE

2

Denmark ALDE

3
icon: ECR ECR
51

Hungary ECR

For (1)

1

Netherlands ECR

For (1)

1

Belgium ECR

For (1)

1

Lithuania ECR

1

Latvia ECR

For (1)

1
icon: Verts/ALE Verts/ALE
49

United Kingdom Verts/ALE

5

Spain Verts/ALE

2

Netherlands Verts/ALE

3

Austria Verts/ALE

2
3

Finland Verts/ALE

2

Latvia Verts/ALE

1

Luxembourg Verts/ALE

For (1)

1

Estonia Verts/ALE

For (1)

1

Denmark Verts/ALE

2

Greece Verts/ALE

Against (1)

1
icon: EFD EFD
7

Netherlands EFD

For (1)

1

Finland EFD

For (1)

1

Slovakia EFD

For (1)

1

Lithuania EFD

For (1)

1

Denmark EFD

For (1)

1

Greece EFD

2
icon: NI NI
16

Spain NI

1

Romania NI

1

Hungary NI

Abstain (1)

3

Belgium NI

For (1)

1
icon: GUE/NGL GUE/NGL
30
6

United Kingdom GUE/NGL

Abstain (1)

1

Spain GUE/NGL

Against (1)

1

Netherlands GUE/NGL

2

Sweden GUE/NGL

Against (1)

1

Latvia GUE/NGL

Abstain (1)

1

Denmark GUE/NGL

1

Greece GUE/NGL

Abstain (1)

2
AmendmentsDossier
14 2008/0255(COD)
2010/02/03 ITRE 6 amendments...
source: PE-438.482
2010/04/07 IMCO 8 amendments...
source: PE-439.867

History

(these mark the time of scraping, not the official date of the change)

committees/5/opinion
False
committees/7/opinion
False
docs/0
date
2008-12-10T00:00:00
docs
summary
type
Legislative proposal
body
EC
docs/1
date
2008-12-10T00:00:00
docs
type
Document attached to the procedure
body
EC
docs/2
date
2008-12-10T00:00:00
docs
type
Document attached to the procedure
body
EC
docs/2/docs/0/url
Old
http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/sec/2008/2668/COM_SEC(2008)2668_EN.pdf
New
http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/sec/2008/2668/COM_SEC(2008)2668_EN.pdf
docs/8
date
2011-01-26T00:00:00
docs
title: SP(2011)610
type
Commission response to text adopted in plenary
body
EC
docs/9
date
2011-01-26T00:00:00
docs
title: SP(2011)610
type
Commission response to text adopted in plenary
body
EC
docs/9/docs/0/url
/oeil/spdoc.do?i=18958&j=0&l=en
docs/11
date
2012-04-12T00:00:00
docs
url: http://www.connefof.europarl.europa.eu/connefof/app/exp/COM(2012)0049 title: COM(2012)0049
type
Contribution
body
IT_SENATE
docs/12
date
2012-04-11T00:00:00
docs
url: https://connectfolx.europarl.europa.eu/connefof/app/exp/COM(2012)0049 title: COM(2012)0049
type
Contribution
body
IT_SENATE
docs/12
date
2012-04-25T00:00:00
docs
url: http://www.connefof.europarl.europa.eu/connefof/app/exp/COM(2012)0049 title: COM(2012)0049
type
Contribution
body
LU_CHAMBER
docs/13
date
2012-04-24T00:00:00
docs
url: https://connectfolx.europarl.europa.eu/connefof/app/exp/COM(2012)0049 title: COM(2012)0049
type
Contribution
body
LU_CHAMBER
docs/13
date
2012-04-12T00:00:00
docs
url: http://www.connefof.europarl.europa.eu/connefof/app/exp/COM(2012)0049 title: COM(2012)0049
type
Contribution
body
PT_PARLIAMENT
docs/14
date
2012-04-11T00:00:00
docs
url: https://connectfolx.europarl.europa.eu/connefof/app/exp/COM(2012)0049 title: COM(2012)0049
type
Contribution
body
PT_PARLIAMENT
events/0/date
Old
2008-12-10T00:00:00
New
2008-12-09T00:00:00
events/11/docs/0/url
Old
http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2011/0632/COM_COM(2011)0632_EN.pdf
New
http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2011/0632/COM_COM(2011)0632_EN.pdf
links/National parliaments/url
Old
http://www.ipex.eu/IPEXL-WEB/dossier/dossier.do?code=COD&year=2008&number=0255&appLng=EN
New
https://ipexl.europarl.europa.eu/IPEXL-WEB/dossier/code=COD&year=2008&number=0255&appLng=EN
committees/0/shadows/4
name
MAŠTÁLKA Jiří
group
European United Left - Nordic Green Left
abbr
GUE/NGL
docs/1/docs/0/url
Old
http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/sec/2008/2668/COM_SEC(2008)2668_EN.pdf
New
http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/sec/2008/2668/COM_SEC(2008)2668_EN.pdf
docs/2/docs/0/url
Old
https://dm.eesc.europa.eu/EESCDocumentSearch/Pages/redresults.aspx?k=(documenttype:AC)(documentnumber:1025)(documentyear:2009)(documentlanguage:EN)
New
https://dmsearch.eesc.europa.eu/search/public?k=(documenttype:AC)(documentnumber:1025)(documentyear:2009)(documentlanguage:EN)
docs/3/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE439.412
New
https://www.europarl.europa.eu/doceo/document/EN&reference=PE439.412
docs/4/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE430.863&secondRef=02
New
https://www.europarl.europa.eu/doceo/document/ITRE-AD-430863_EN.html
docs/5/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE439.345&secondRef=02
New
https://www.europarl.europa.eu/doceo/document/IMCO-AD-439345_EN.html
docs/6/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE441.030
New
https://www.europarl.europa.eu/doceo/document/EN&reference=PE441.030
docs/7/docs/0/url
Old
http://www.europarl.europa.eu/doceo/document/A-7-2010-0289_EN.html
New
https://www.europarl.europa.eu/doceo/document/A-7-2010-0289_EN.html
docs/8/docs/0/url
/oeil/spdoc.do?i=18958&j=0&l=en
docs/9/docs/0/url
Old
https://dm.eesc.europa.eu/EESCDocumentSearch/Pages/redresults.aspx?k=(documenttype:AC)(documentnumber:0468)(documentyear:2012)(documentlanguage:EN)
New
https://dmsearch.eesc.europa.eu/search/public?k=(documenttype:AC)(documentnumber:0468)(documentyear:2012)(documentlanguage:EN)
docs/10/docs/0/url
Old
https://dm.eesc.europa.eu/EESCDocumentSearch/Pages/redresults.aspx?k=(documenttype:AC)(documentnumber:0810)(documentyear:2012)(documentlanguage:FR)
New
https://dmsearch.eesc.europa.eu/search/public?k=(documenttype:AC)(documentnumber:0810)(documentyear:2012)(documentlanguage:FR)
events/1/type
Old
Committee referral announced in Parliament, 1st reading/single reading
New
Committee referral announced in Parliament, 1st reading
events/2/type
Old
Committee referral announced in Parliament, 1st reading/single reading
New
Committee referral announced in Parliament, 1st reading
events/4/type
Old
Vote in committee, 1st reading/single reading
New
Vote in committee, 1st reading
events/5
date
2010-10-19T00:00:00
type
Committee report tabled for plenary, 1st reading
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/A-7-2010-0289_EN.html title: A7-0289/2010
events/5
date
2010-10-19T00:00:00
type
Committee report tabled for plenary, 1st reading/single reading
body
EP
docs
url: http://www.europarl.europa.eu/doceo/document/A-7-2010-0289_EN.html title: A7-0289/2010
events/6/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=20101122&type=CRE
New
https://www.europarl.europa.eu/doceo/document/EN&reference=20101122&type=CRE
events/8
date
2010-11-24T00:00:00
type
Decision by Parliament, 1st reading
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/TA-7-2010-0430_EN.html title: T7-0430/2010
summary
events/8
date
2010-11-24T00:00:00
type
Decision by Parliament, 1st reading/single reading
body
EP
docs
url: http://www.europarl.europa.eu/doceo/document/TA-7-2010-0430_EN.html title: T7-0430/2010
summary
events/11/docs/0/url
Old
http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2011/0632/COM_COM(2011)0632_EN.pdf
New
http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2011/0632/COM_COM(2011)0632_EN.pdf
procedure/Modified legal basis
Rules of Procedure EP 150
procedure/Other legal basis
Rules of Procedure EP 159
committees/0/date
  • 2009-07-21T00:00:00
committees/0/rapporteur/0/date
2009-07-21T00:00:00
committees/1/date
    committees/2/date
    • 2012-03-01T00:00:00
    committees/2/rapporteur/0/date
    2012-03-01T00:00:00
    committees/3/date
    • 2009-09-16T00:00:00
    committees/3/rapporteur/0/date
    2009-09-16T00:00:00
    committees/4/date
    • 2009-09-14T00:00:00
    committees/4/rapporteur/0/date
    2009-09-14T00:00:00
    committees/6/date
      committees/7/date
        committees/8/date
          docs/0/docs/0/url
          Old
          http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/sec/2008/2667/COM_SEC(2008)2667_EN.pdf
          New
          http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/sec/2008/2667/COM_SEC(2008)2667_EN.pdf
          docs/1/docs/0/url
          Old
          http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/sec/2008/2668/COM_SEC(2008)2668_EN.pdf
          New
          http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/sec/2008/2668/COM_SEC(2008)2668_EN.pdf
          docs/7/docs/0/url
          Old
          http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A7-2010-289&language=EN
          New
          http://www.europarl.europa.eu/doceo/document/A-7-2010-0289_EN.html
          docs/8/body
          EC
          events/0/docs/0/url
          Old
          http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2008/0662/COM_COM(2008)0662_EN.pdf
          New
          http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2008/0662/COM_COM(2008)0662_EN.pdf
          events/5/docs/0/url
          Old
          http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A7-2010-289&language=EN
          New
          http://www.europarl.europa.eu/doceo/document/A-7-2010-0289_EN.html
          events/8/docs/0/url
          Old
          http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P7-TA-2010-430
          New
          http://www.europarl.europa.eu/doceo/document/TA-7-2010-0430_EN.html
          activities
          • date: 2008-12-10T00:00:00 docs: url: http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2008/0662/COM_COM(2008)0662_EN.pdf title: COM(2008)0662 type: Legislative proposal published celexid: CELEX:52008PC0662:EN body: EC commission: DG: url: http://ec.europa.eu/dgs/health_consumer/index_en.htm title: Health and Consumers Commissioner: BORG Tonio type: Legislative proposal published
          • date: 2009-01-13T00:00:00 body: EP type: Committee referral announced in Parliament, 1st reading/single reading committees: body: EP shadows: group: PPE name: ROSSI Oreste group: S&D name: PARGNEAUX Gilles group: ALDE name: PARVANOVA Antonyia group: Verts/ALE name: SCHLYTER Carl group: ECR name: CABRNOCH Milan group: GUE/NGL name: MAŠTÁLKA Jiří responsible: True committee: ENVI date: 2012-03-01T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: PPE name: FJELLNER Christofer body: EP responsible: True committee: ENVI date: 2009-07-21T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: PPE name: FJELLNER Christofer body: EP responsible: True committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP responsible: False committee_full: Internal Market and Consumer Protection committee: IMCO body: EP responsible: False committee: IMCO date: 2009-09-14T00:00:00 committee_full: Internal Market and Consumer Protection rapporteur: group: S&D name: CORREIA DE CAMPOS António Fernando body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE body: EP responsible: False committee: ITRE date: 2009-09-16T00:00:00 committee_full: Industry, Research and Energy rapporteur: group: ALDE name: CHATZIMARKAKIS Jorgo
          • date: 2009-10-19T00:00:00 body: EP type: Committee referral announced in Parliament, 1st reading/single reading committees: body: EP shadows: group: PPE name: ROSSI Oreste group: S&D name: PARGNEAUX Gilles group: ALDE name: PARVANOVA Antonyia group: Verts/ALE name: SCHLYTER Carl group: ECR name: CABRNOCH Milan group: GUE/NGL name: MAŠTÁLKA Jiří responsible: True committee: ENVI date: 2012-03-01T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: PPE name: FJELLNER Christofer body: EP responsible: True committee: ENVI date: 2009-07-21T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: PPE name: FJELLNER Christofer body: EP responsible: True committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP responsible: False committee_full: Internal Market and Consumer Protection committee: IMCO body: EP responsible: False committee: IMCO date: 2009-09-14T00:00:00 committee_full: Internal Market and Consumer Protection rapporteur: group: S&D name: CORREIA DE CAMPOS António Fernando body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE body: EP responsible: False committee: ITRE date: 2009-09-16T00:00:00 committee_full: Industry, Research and Energy rapporteur: group: ALDE name: CHATZIMARKAKIS Jorgo
          • body: CSL meeting_id: 2980 docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=2980*&MEET_DATE=30/11/2009 type: Debate in Council title: 2980 council: Employment, Social Policy, Health and Consumer Affairs date: 2009-11-30T00:00:00 type: Council Meeting
          • date: 2010-09-28T00:00:00 body: EP committees: body: EP shadows: group: PPE name: ROSSI Oreste group: S&D name: PARGNEAUX Gilles group: ALDE name: PARVANOVA Antonyia group: Verts/ALE name: SCHLYTER Carl group: ECR name: CABRNOCH Milan group: GUE/NGL name: MAŠTÁLKA Jiří responsible: True committee: ENVI date: 2012-03-01T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: PPE name: FJELLNER Christofer body: EP responsible: True committee: ENVI date: 2009-07-21T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: PPE name: FJELLNER Christofer body: EP responsible: True committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP responsible: False committee_full: Internal Market and Consumer Protection committee: IMCO body: EP responsible: False committee: IMCO date: 2009-09-14T00:00:00 committee_full: Internal Market and Consumer Protection rapporteur: group: S&D name: CORREIA DE CAMPOS António Fernando body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE body: EP responsible: False committee: ITRE date: 2009-09-16T00:00:00 committee_full: Industry, Research and Energy rapporteur: group: ALDE name: CHATZIMARKAKIS Jorgo type: Vote in committee, 1st reading/single reading
          • date: 2010-10-19T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A7-2010-289&language=EN type: Committee report tabled for plenary, 1st reading/single reading title: A7-0289/2010 body: EP committees: body: EP shadows: group: PPE name: ROSSI Oreste group: S&D name: PARGNEAUX Gilles group: ALDE name: PARVANOVA Antonyia group: Verts/ALE name: SCHLYTER Carl group: ECR name: CABRNOCH Milan group: GUE/NGL name: MAŠTÁLKA Jiří responsible: True committee: ENVI date: 2012-03-01T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: PPE name: FJELLNER Christofer body: EP responsible: True committee: ENVI date: 2009-07-21T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: PPE name: FJELLNER Christofer body: EP responsible: True committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP responsible: False committee_full: Internal Market and Consumer Protection committee: IMCO body: EP responsible: False committee: IMCO date: 2009-09-14T00:00:00 committee_full: Internal Market and Consumer Protection rapporteur: group: S&D name: CORREIA DE CAMPOS António Fernando body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE body: EP responsible: False committee: ITRE date: 2009-09-16T00:00:00 committee_full: Industry, Research and Energy rapporteur: group: ALDE name: CHATZIMARKAKIS Jorgo type: Committee report tabled for plenary, 1st reading/single reading
          • date: 2010-11-22T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=20101122&type=CRE type: Debate in Parliament title: Debate in Parliament body: EP type: Debate in Parliament
          • date: 2010-11-24T00:00:00 docs: url: http://www.europarl.europa.eu/oeil/popups/sda.do?id=18958&l=en type: Results of vote in Parliament title: Results of vote in Parliament url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P7-TA-2010-430 type: Decision by Parliament, 1st reading/single reading title: T7-0430/2010 body: EP type: Results of vote in Parliament
          • body: CSL meeting_id: 3053 docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=3053*&MEET_DATE=06/12/2010 type: Debate in Council title: 3053 council: Employment, Social Policy, Health and Consumer Affairs date: 2010-12-06T00:00:00 type: Council Meeting
          • body: CSL meeting_id: 3095 docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=3095*&MEET_DATE=30/05/2011 type: Debate in Council title: 3095 council: Employment, Social Policy, Health and Consumer Affairs date: 2011-05-30T00:00:00 type: Council Meeting
          • date: 2011-10-11T00:00:00 docs: url: http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2011/0632/COM_COM(2011)0632_EN.pdf title: COM(2011)0632 type: Modified legislative proposal published celexid: CELEX:52011PC0632:EN body: EC commission: DG: url: http://ec.europa.eu/dgs/health_consumer/index_en.htm title: Health and Consumers Commissioner: BORG Tonio type: Modified legislative proposal published
          • date: 2012-02-10T00:00:00 docs: url: http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2012/0049/COM_COM(2012)0049(COR1)_EN.pdf title: COM(2012)0049 type: Amended legislative proposal for reconsultation published celexid: CELEX:52012PC0049:EN body: EC commission: DG: url: http://ec.europa.eu/dgs/health_consumer/index_en.htm title: Health and Consumers Commissioner: BORG Tonio type: Amended legislative proposal for reconsultation published
          • date: 2012-02-10T00:00:00 body: EP/CSL type: Formal reconsultation of Parliament
          • date: 2014-05-21T00:00:00 body: EC commission: DG: url: http://ec.europa.eu/dgs/health_consumer/index_en.htm title: Health and Consumers Commissioner: BORG Tonio type: Proposal withdrawn by Commission
          commission
          • body: EC dg: Health and Food Safety commissioner: BORG Tonio
          committees/0/associated
          False
          committees/0/date
          Old
          2012-03-01T00:00:00
          New
          • 2009-07-21T00:00:00
          committees/0/rapporteur/0
          name
          FJELLNER Christofer
          group
          European People's Party (Christian Democrats)
          abbr
          PPE
          committees/0/rapporteur/0
          group
          PPE
          name
          FJELLNER Christofer
          committees/0/responsible
          True
          committees/0/shadows/0
          name
          PARGNEAUX Gilles
          group
          Progressive Alliance of Socialists and Democrats
          abbr
          S&D
          committees/0/shadows/0
          group
          PPE
          name
          ROSSI Oreste
          committees/0/shadows/1
          name
          CHATZIMARKAKIS Jorgo
          group
          Alliance of Liberals and Democrats for Europe
          abbr
          ALDE
          committees/0/shadows/1
          group
          S&D
          name
          PARGNEAUX Gilles
          committees/0/shadows/2
          name
          SCHLYTER Carl
          group
          Greens/European Free Alliance
          abbr
          Verts/ALE
          committees/0/shadows/2
          group
          ALDE
          name
          PARVANOVA Antonyia
          committees/0/shadows/3
          name
          YANNAKOUDAKIS Marina
          group
          European Conservatives and Reformists
          abbr
          ECR
          committees/0/shadows/3
          group
          Verts/ALE
          name
          SCHLYTER Carl
          committees/0/shadows/4
          name
          MAŠTÁLKA Jiří
          group
          European United Left - Nordic Green Left
          abbr
          GUE/NGL
          committees/0/shadows/4
          group
          ECR
          name
          CABRNOCH Milan
          committees/0/shadows/5
          name
          ROSBACH Anna
          group
          Europe of Freedom and Democracy
          abbr
          EFD
          committees/0/shadows/5
          group
          GUE/NGL
          name
          MAŠTÁLKA Jiří
          committees/0/type
          Responsible Committee
          committees/1/associated
          False
          committees/1/date
          Old
          2009-07-21T00:00:00
          New
           
          committees/1/rapporteur
          • group: PPE name: FJELLNER Christofer
          committees/1/responsible
          True
          committees/1/type
          Former Responsible Committee
          committees/2/associated
          False
          committees/2/date
          • 2012-03-01T00:00:00
          committees/2/rapporteur
          • name: FJELLNER Christofer group: European People's Party (Christian Democrats) abbr: PPE
          committees/2/responsible
          True
          committees/2/type
          Former Responsible Committee
          committees/3/associated
          False
          committees/3/committee
          Old
          IMCO
          New
          ITRE
          committees/3/committee_full
          Old
          Internal Market and Consumer Protection
          New
          Industry, Research and Energy
          committees/3/date
          • 2009-09-16T00:00:00
          committees/3/rapporteur
          • name: CHATZIMARKAKIS Jorgo group: Alliance of Liberals and Democrats for Europe abbr: ALDE
          committees/3/responsible
          False
          committees/3/type
          Committee Opinion
          committees/4/associated
          False
          committees/4/date
          Old
          2009-09-14T00:00:00
          New
          • 2009-09-14T00:00:00
          committees/4/rapporteur/0
          name
          CORREIA DE CAMPOS António Fernando
          group
          Progressive Alliance of Socialists and Democrats
          abbr
          S&D
          committees/4/rapporteur/0
          group
          S&D
          name
          CORREIA DE CAMPOS António Fernando
          committees/4/responsible
          False
          committees/4/type
          Committee Opinion
          committees/5/associated
          False
          committees/5/opinion
          False
          committees/5/responsible
          False
          committees/5/type
          Former Committee Opinion
          committees/6/associated
          False
          committees/6/committee
          Old
          ITRE
          New
          IMCO
          committees/6/committee_full
          Old
          Industry, Research and Energy
          New
          Internal Market and Consumer Protection
          committees/6/date
          Old
          2009-09-16T00:00:00
          New
           
          committees/6/rapporteur
          • group: ALDE name: CHATZIMARKAKIS Jorgo
          committees/6/responsible
          False
          committees/6/type
          Former Committee Opinion
          committees/7
          type
          Former Committee Opinion
          body
          EP
          associated
          False
          committee_full
          Industry, Research and Energy
          committee
          ITRE
          date
          committees/8
          type
          Former Committee Opinion
          body
          EP
          associated
          False
          committee_full
          Internal Market and Consumer Protection
          committee
          IMCO
          date
          council
          • body: CSL type: Council Meeting council: Employment, Social Policy, Health and Consumer Affairs meeting_id: 3095 url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=3095*&MEET_DATE=30/05/2011 date: 2011-05-30T00:00:00
          • body: CSL type: Council Meeting council: Employment, Social Policy, Health and Consumer Affairs meeting_id: 3053 url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=3053*&MEET_DATE=06/12/2010 date: 2010-12-06T00:00:00
          • body: CSL type: Council Meeting council: Employment, Social Policy, Health and Consumer Affairs meeting_id: 2980 url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=2980*&MEET_DATE=30/11/2009 date: 2009-11-30T00:00:00
          docs
          • date: 2008-12-10T00:00:00 docs: url: http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/sec/2008/2667/COM_SEC(2008)2667_EN.pdf title: SEC(2008)2667 url: https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=SECfinal&an_doc=2008&nu_doc=2667 title: EUR-Lex type: Document attached to the procedure body: EC
          • date: 2008-12-10T00:00:00 docs: url: http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/sec/2008/2668/COM_SEC(2008)2668_EN.pdf title: SEC(2008)2668 url: https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=SECfinal&an_doc=2008&nu_doc=2668 title: EUR-Lex type: Document attached to the procedure body: EC
          • date: 2009-06-10T00:00:00 docs: url: https://dm.eesc.europa.eu/EESCDocumentSearch/Pages/redresults.aspx?k=(documenttype:AC)(documentnumber:1025)(documentyear:2009)(documentlanguage:EN) title: CES1025/2009 type: Economic and Social Committee: opinion, report body: ESC
          • date: 2010-03-10T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE439.412 title: PE439.412 type: Committee draft report body: EP
          • date: 2010-03-24T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE430.863&secondRef=02 title: PE430.863 committee: ITRE type: Committee opinion body: EP
          • date: 2010-04-30T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE439.345&secondRef=02 title: PE439.345 committee: IMCO type: Committee opinion body: EP
          • date: 2010-05-04T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE441.030 title: PE441.030 type: Amendments tabled in committee body: EP
          • date: 2010-10-19T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A7-2010-289&language=EN title: A7-0289/2010 type: Committee report tabled for plenary, 1st reading/single reading body: EP
          • date: 2011-01-26T00:00:00 docs: url: /oeil/spdoc.do?i=18958&j=0&l=en title: SP(2011)610 type: Commission response to text adopted in plenary
          • date: 2012-02-22T00:00:00 docs: url: https://dm.eesc.europa.eu/EESCDocumentSearch/Pages/redresults.aspx?k=(documenttype:AC)(documentnumber:0468)(documentyear:2012)(documentlanguage:EN) title: CES0468/2012 type: Economic and Social Committee: opinion, report body: ESC
          • date: 2012-03-28T00:00:00 docs: url: https://dm.eesc.europa.eu/EESCDocumentSearch/Pages/redresults.aspx?k=(documenttype:AC)(documentnumber:0810)(documentyear:2012)(documentlanguage:FR) title: CES0810/2012 type: Economic and Social Committee: opinion, report body: ESC
          • date: 2012-04-12T00:00:00 docs: url: http://www.connefof.europarl.europa.eu/connefof/app/exp/COM(2012)0049 title: COM(2012)0049 type: Contribution body: IT_SENATE
          • date: 2012-04-25T00:00:00 docs: url: http://www.connefof.europarl.europa.eu/connefof/app/exp/COM(2012)0049 title: COM(2012)0049 type: Contribution body: LU_CHAMBER
          • date: 2012-04-12T00:00:00 docs: url: http://www.connefof.europarl.europa.eu/connefof/app/exp/COM(2012)0049 title: COM(2012)0049 type: Contribution body: PT_PARLIAMENT
          events
          • date: 2008-12-10T00:00:00 type: Legislative proposal published body: EC docs: url: http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2008/0662/COM_COM(2008)0662_EN.pdf title: COM(2008)0662 url: https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=2008&nu_doc=662 title: EUR-Lex summary: PURPOSE: to promote public health in the Community by establishing harmonised rules on the provision of information on medicinal products subject to medical prescription. PROPOSED ACT: Directive of the European Parliament and of the Council. BACKGROUND: Directive 2001/83/EC on the Community code relating to medicinal products for human use provides for a harmonised framework on advertising of medicines at Community level, the application of which remains a responsibility of Member States. This legislation prohibits the advertising to the general public of medicines subject to prescription. However, neither the Directive nor Regulation (EC) No 726/2004 include detailed provisions on information on medicinal products, providing only that certain information supply activities are exempted from the advertising provisions. Therefore, Community legislation does not prevent Member States from establishing their own approaches regarding the provision of information on medicinal products as long as the above mentioned rules on advertising are respected. In addition, the boundaries between advertising and information, and therefore the field of application of the legislation's restrictions on advertising, are not interpreted consistently across the Community. Pursuant to Directive 2001/83/EC, a Communication from the Commission to the European Parliament and the Council concerning the "Report on current practices with regard to the provision of information to patients on medicinal products" (see COD/1999/0134 under “ Follow-up documents ”) was adopted and submitted to the European Parliament and the Council on 20 December 2007. According to the Report, rules and practices on what information can be made available vary significantly among Member States. Moreover, divergences in terms of rules and practices on what information can be made available have a negative impact on legal certainty for marketing authorisation holders with cross-border activity. CONTENT: the Commission proposes to amend Directive 2001/83/EC and Regulation (EC) No 726/2004 (see also COD/2008/0256 ) to address the gap in the current pharmaceutical legislation as regards the provision of information to the general public on prescription-only medicinal product for human use. The aim is to enhance the rational use of these medicines, while ensuring that the legislative framework continues to prohibit direct-to-consumer advertising of prescription-only medicines. The main elements of the proposals can be summarised as follows: clarifying that the provision of information on prescription-only medicines directly to the public by marketing authorisation holders is allowed, without prejudice to the prohibition on advertising, provided that clearly defined conditions are fulfilled; establishing harmonised conditions on the content of information which marketing authorisation holders are allowed to disseminate (information approved by the competent authorities for granting marketing authorisation, whether used literally or presented in a different way, and other limited medicine-related information); establishing harmonised quality standards for such information, to ensure that it is of high-quality and non-promotional; determining the authorised channels of information provision , in order to exclude unsolicited means of dissemination; introducing the obligation for Member States to establish a monitoring system to ensure that the abovementioned provisions on content of information, quality standards and dissemination channels are complied with and ensure enforcement in case of non-compliance. The proposal leaves it up to the Member States to decide the most appropriate monitoring mechanisms, but lays down a general rule that monitoring should take place after dissemination of information, with certain exceptions (where prior approval would be necessary) in the case of certain modalities of information where the distinction between advertising and non-promotional information is more difficult to establish. For products authorised in accordance with Regulation (EC) No 726/2004, certain approval tasks are given to the European Medicines Agency; establishing specific monitoring rules for information disseminated through websites , to take account of the cross-border nature of information provided over the Internet and to allow Member State cooperation and avoid duplication of monitoring.
          • date: 2009-01-13T00:00:00 type: Committee referral announced in Parliament, 1st reading/single reading body: EP
          • date: 2009-10-19T00:00:00 type: Committee referral announced in Parliament, 1st reading/single reading body: EP
          • date: 2009-11-30T00:00:00 type: Debate in Council body: CSL docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=2980*&MEET_DATE=30/11/2009 title: 2980 summary: On the basis of progress reports, the Presidency informed the Council of the state of play in the negotiations on two parts of the "pharmaceutical package": preventing falsified medicines from entering into the legal supply chain of medicinal products and the strengthening and rationalising of the current pharmacovigilance system. Under the Swedish Presidency, the preparatory bodies of the Council pursued their work with high priority on these two parts of the package. 1) Concerning the draft directive on preventing the entry into the legal supply chain of falsified medicinal products , the working group reached tentative agreement on a number of technical aspects, including: · the definition of "falsified medicinal products"; · the proposed definition of ''trading of medicinal products'' has been changed to ''brokering of medicinal products'' and amended, thereby clarifying which actors in the supply chain should be subject to the responsibilities of brokers. The proposed introduction of obligations for brokers aim to reinforce the traceability of medicinal products; · a clarification of the relationship between the proposed new provisions in Directive 2001/83/EC and Community legislation on intellectual property rights. Other elements of the proposal still need further discussion, notably with regard to the strengthening of controls of non active substances used in pharmaceuticals (excipients) and the proposed safety features aiming to render falsification more difficult. The proposal includes provisions requiring the accreditation of third party auditors of Good Manufacturing Practices and Good Distribution Practices. A majority of delegations object to accreditation, since they maintain that such a system could result in a transfer of responsibility from manufacturers and importers as well as make enforcement by national competent authorities more difficult. The Presidency has therefore proposed to delete the provisions regarding accreditation from the text. Some delegations have expressed an interest in the possibility of establishing third party accreditation at a national level. 2) Concerning the proposals for a regulation and a directive on strengthening the EU system for the safety monitoring of medicinal products ("pharmacovigilance"), the working group reached tentative agreement on a number of questions including: · a clarification of the relation between the proposed new provisions in Directive 2001/83/EC and Regulation (EC) 726/2004 on the one hand and the Community legislation on protection of personal data on the other hand; · a strengthening of the role of the Pharmacovigilance Risk Assessment Committee (PRAC) in relation to the Committee for Medicinal Products for Human Use and to the Coordination Group set up by Article 27 of Directive 2001/83/EC (CMD), including an obligation for these last two bodies to explain any differences in opinion compared to the PRAC; · a change in the composition of the PRAC and in the method for nominating the PRAC members so that all Member States will be represented; · the inclusion of a requirement for the Agency, in collaboration with the Member States and the Commission, to draw up functional specifications for the Eudravigilance database which will take account of the role and experience of national competent authorities for pharmacovigilance. The new reporting obligations to Eudravigilance will not apply until these specifications are met and to this end a transitional period is envisaged; · the legal status of CMD opinions and how they are implemented in Member States. Here, text redrafting proposals are under legal scrutiny. The Working Party has continued to discuss other central provisions of the proposals, mainly in relation to the Community Procedure and Referrals, the Recording and Reporting of adverse reactions, the Periodic Safety Update Reports and the Post Authorisation Safety Studies. A number of issues still require further examination, such as the recording and reporting of adverse reactions and the proposed list of medicinal products for human use under intensive monitoring. At this stage, all delegations have a general scrutiny reservation on the entire proposal while the Danish, Maltese and United Kingdom delegations have parliamentary scrutiny reservations. 3) With regard to the third part of the "pharmaceutical package", the proposals for a regulation and a directive concerning information for the general public on medicinal products, the Presidency recalled the strong concerns of many Member States. The Commission made it clear that it is prepared to show flexibility in order to find a common basis for the future negotiations.
          • date: 2010-09-28T00:00:00 type: Vote in committee, 1st reading/single reading body: EP summary: The Committee on the Environment, Public Health and Food Safety adopted the report drafted by Christofer FJELLNER (EPP, SE) on the proposal for a regulation of the European Parliament and of the Council on amending, as regards information to the general public on medicinal products for human use subject to medical prescription, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. The committee recommended that the European Parliament’s position at first reading under the ordinary legislative procedure (formerly known as the codecision procedure) should be to amend the Commission proposal as follows: Patients’ rights : Members consider that the Amending Directive has to focus on the patients and their interests and it has to be reflected in the Amending Regulation as well. The new provisions of the Amending Directive have to emphasise the right of patients for information instead of the right of the pharmaceutical companies to disseminate information. Information : the report highlights the urgent need for a more precise distinction between advertising and information . Non-promotional information on medicinal products must be made available to patients and to the general public by marketing authorisation holders according to the "pull principle" whereby patients/the public have access to information if they need it (contrary to the "push principle" whereby the marketing authorisation holders disseminate information among the patients and the general public). In this context, Members propose an amendment relating to information not approved by competent authorities during the registration of medicinal products and is in fact hidden “push” information. Any relevant information relating to studies is included in the patient leaflet and the Summary of Product Characteristics (SmPC), which is part of the registration file for approval. Extending the time-limit for information : Members propose extending the timeline for the tacit acceptance of the information from 60 to 120 days in order to meet the organisational needs of the Agency and to ensure that the companies remain fully liable for the information they provide to the general public. If the Agency asks for changes to a document submitted by the marketing authorisation holder, and if the latter resubmits an improved proposal within 30 working days, the Agency shall communicate its response to the new proposal within 60 working days. Database on medicinal products : the report underlines that strengthening the EMEA’s role with regard to information for the public on medicinal products for which a medical prescription is required is crucial in order to ensure that all citizens have equal access to high-quality information. The management of the database of information for the public should comply with exemption criteria for that information. The database should be publicly accessible as a prime source of objective information. With this aim in mind, the Member States, the Commission and the Agency itself should make every effort to ensure that proper use is made of this database. Members insist on promoting existing sources of independent reliable health information. There are many sources of independent and evidence-based information on treatment choices available within the European Union. These resources take into account cultural specificities and contexts for the population, including health determinants. They are developed by health authorities, medical products agencies, healthcare assessment bodies, healthcare providers, healthcare professionals, consumer organisations, and independent patients’ organisations. These information sources should be actively promoted to the general public. Agency’s budget : the report requests that in the event that the additional costs incurred by the Agency as a result of its preliminary checking of certain types of information pursuant to this Regulation are not covered by the fees payable by the marketing authorisation holders for this purpose, the amount of the European Union’s contribution to the Agency’s budget should be reviewed. Accordingly, efforts should be initiated at Member State level with a view to the possible amendment of the European Union’s contribution to the Agency.
          • date: 2010-10-19T00:00:00 type: Committee report tabled for plenary, 1st reading/single reading body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A7-2010-289&language=EN title: A7-0289/2010
          • date: 2010-11-22T00:00:00 type: Debate in Parliament body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=20101122&type=CRE title: Debate in Parliament
          • date: 2010-11-24T00:00:00 type: Results of vote in Parliament body: EP docs: url: https://oeil.secure.europarl.europa.eu/oeil/popups/sda.do?id=18958&l=en title: Results of vote in Parliament
          • date: 2010-11-24T00:00:00 type: Decision by Parliament, 1st reading/single reading body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P7-TA-2010-430 title: T7-0430/2010 summary: The European Parliament adopted by 564 votes to 41, with 45 abstentions, a legislative resolution on the proposal for a regulation of the European Parliament and of the Council on amending, as regards information to the general public on medicinal products for human use subject to medical prescription, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. It adopted its position at first reading under the ordinary legislative procedure (formerly known as the codecision procedure) in which it amends the Commission proposal as follows: Patients’ rights : Parliament considers that the Amending Directive has to focus on the patients and their interests and it has to be reflected in the Amending Regulation as well. The new provisions of the Amending Directive have to emphasise the right of patients for information instead of the right of the pharmaceutical companies to disseminate information. Information : the resolution highlights the urgent need for a more precise distinction between advertising and information. Non-promotional information on medicinal products must be made available to patients and to the general public by marketing authorisation holders according to the "pull principle" whereby patients/the public have access to information if they need it (contrary to the "push principle" whereby the marketing authorisation holders disseminate information among the patients and the general public). In this context, Parliament proposes an amendment relating to information not approved by competent authorities during the registration of medicinal products and is in fact hidden “push” information. Any relevant information relating to studies is included in the patient leaflet and the Summary of Product Characteristics (SmPC), which is part of the registration file for approval. Time-limit for information : The Agency may object to the information submitted or parts thereof on grounds related to non-compliance with the provisions of Title VIIIa of Directive 2001/83/EC within 90 days (instead of 60 days) after receipt of the notification. If the Agency does not object within 90 days, the information shall be deemed accepted and may be published. The marketing authorisation holder shall remain fully liable and responsible for the information provided in all cases. If the Agency asks for changes to be made to a document submitted by the marketing authorisation holder, and if the latter resubmits an improved proposal within 30 working days, the Agency shall communicate its response to the new proposal within 60 working days. Database on medicinal products : the resolution underlines that strengthening the EMEA’s role with regard to information for the public on medicinal products for which a medical prescription is required is crucial in order to ensure that all citizens have equal access to high-quality information. The management of the database of information for the public should comply with exemption criteria for that information. The database on medicinal products should be accessible to the general public, in all official languages of the Union and should be managed independently of the commercial interests of pharmaceutical companies. It should be publicly accessible as a prime source of objective information. With this aim in mind, the Member States, the Commission and the Agency itself should make every effort to ensure that proper use is made of this database. Members insist on promoting existing sources of independent reliable health information. There are many sources of independent and evidence-based information on treatment choices available within the European Union. These resources take into account cultural specificities and contexts for the population, including health determinants. They are developed by health authorities, medical products agencies, healthcare assessment bodies, healthcare providers, healthcare professionals, consumer organisations, and independent patients’ organisations. These information sources should be actively promoted to the general public. Agency’s budget : the resolution requests that in the event that the additional costs incurred by the Agency as a result of its preliminary checking of certain types of information pursuant to this Regulation are not covered by the fees payable by the marketing authorisation holders for this purpose, the amount of the European Union’s contribution to the Agency’s budget should be reviewed. Accordingly, efforts should be initiated at Member State level with a view to the possible amendment of the European Union’s contribution to the Agency.
          • date: 2010-12-06T00:00:00 type: Debate in Council body: CSL docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=3053*&MEET_DATE=06/12/2010 title: 3053 summary: The Commission expressed its willingness to modify its proposal concerning information to the general public on medicinal products for human use which are subject to prescription in order to take into account the concerns of the Member States. The incoming Hungarian Presidency announced its willingness to address this file as a matter of priority as soon as the modified proposal has been presented.
          • date: 2011-05-30T00:00:00 type: Debate in Council body: CSL docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=3095*&MEET_DATE=30/05/2011 title: 3095
          • date: 2011-10-11T00:00:00 type: Modified legislative proposal published body: EC docs: url: http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2011/0632/COM_COM(2011)0632_EN.pdf title: COM(2011)0632 url: https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=2011&nu_doc=632 title: EUR-Lex summary: The Commission presents an amended proposal for a Regulation of the European Parliament and of the Council on information to the general public on medicinal products subject to medical prescription. Incorporated within the amended proposal are amendments proposed by the European Parliament at its first reading which are acceptable to the Commission. 12 amendments on the proposal were adopted by Parliament at first reading . The Commission considers that a majority of Parliament's amendments are acceptable in full, in principle, or in part, as they maintain the aims and overall scheme of the proposal. The Commission therefore incorporates in full or in part, the following amendments of the European Parliament in the amended proposal: it underlines that in the Commission Communication transmitted on 20 December 2007 concerning the "Report on current practices with regard to the provision of information to patients on medicinal products" the need for a more precise distinction between advertising and information was highlighted; it is specified that the new Title introduced in Directive 2001/83/EC is intended to place emphasis on the rights and interests of patients. It also states that although the pre-control of information is performed by the Agency for centrally approved medicinal products, the monitoring of the information rests with Member States. It is appropriate to ensure consistently that the Agency is also responsible for the control of the information made available through Internet websites registered in the Member States. Specific provisions are introduced to clarify the operation of this control mechanism in such case of information made available through Internet websites registered with the Member States. The Commission acknowledges that a number of Member States have expressed concerns regarding conformity with their national constitutions. The Commission is prepared to enter into a dialogue with those concerned to find suitable solutions while fully respecting the objectives of this Regulation; it provides for the procedure regarding cases when the Agency requests changes within the information submitted for control and for the fees applicable which should be proportionate to the additional work. Considering that the normal delay is 60 days, the subsequent delay should be of 30 days; the text provides that the EudraPharm database it should be available in all EU languages. Such a change has been introduced as regards the lay-out of the database. However, the information contained in the database will be available in the languages of Member States where the medicinal product is authorised. In another respect, it is not necessary to further specify that the information provided is designed for non-experts, as it is already provided that it should be worded in an appropriate and comprehensible manner. EudraPharm should be actively promoted to European citizens. This should be done through the development of the European medicines web-portal established by Regulation (EU) No 1235/2010 as the central point of access to information about medicinal products. However, it is not appropriate that information available on marketing authorisation holder websites is reproduced on EudraPharm, which is a public database. Pharmacovigilance: in addition to the changes introduced on the basis of the European Parliament resolutions regarding the Commission proposals on information to patients, the Commission considers that limited changes to Regulation (EC) No 726/2004 in the area of pharmacovigilance should be introduced. Regulation (EC) No 726/2004 has been recently amended by Regulation (EU) No 1235/2010 to revise the EU pharmacovigilance system. Since Regulation (EU) No 1235/2010 has as legal basis Article 168(4)(c) of TFUE, the amended proposal should also be based on Article 168(4)(c) of TFUE . Regulation (EU) No 1235/2010 substantially strengthens the legal framework for the surveillance of medicinal products in the EU. However, in view of recent pharmacovigilance events in the EU, the Commission has detected certain areas where the legislation could be further strengthened. Therefore: the new public list of medicinal products subject to additional monitoring introduced by Regulation (EU) No 1235/2010 will not necessarily include all medicinal products subject to post-authorisation safety conditions. Competent authorities will have to decide on a case-by-case basis whether to make public the fact that products are subject to strengthened surveillance. For the sake of fuller transparency as regards products under special surveillance, the text is modified to systematically include medicinal products that are subject to conditions and requirements with regard to safety; a new provision is introduced to avoid a situation where the voluntary withdrawal of a marketing authorisation or product by the holder could lead to safety issues not being addressed in the EU. It clarifies the information obligations of the marketing authorisation holder. Lastly, the text clarifies the scope of this provision and the EU procedures set out in Directive 2001/83/EC.
          • date: 2012-02-10T00:00:00 type: Formal reconsultation of Parliament body: EP/CSL
          • date: 2012-02-10T00:00:00 type: Amended legislative proposal for reconsultation published body: EC docs: url: http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2012/0049/COM_COM(2012)0049(COR1)_EN.pdf title: COM(2012)0049 url: https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=2012&nu_doc=49 title: EUR-Lex summary: The Commission presents, for re-consultation , an amended proposal for a Regulation of the European Parliament and the Council on information to the general public on medicinal products subject to medical prescription. The amended proposal incorporates the amendments proposed by the European Parliament at first reading on 24 November 2010 as the Commission considers them acceptable. The general policy objectives of the proposals to amend Directive 2001/83/EC and Regulation (EC) No 726/2004 are in line with the overall objectives of the EU pharmaceutical legislation. This amended proposal is in line with those objectives to include measures setting high standards of safety for medicinal products. Therefore, in view of the entry into force of the Treaty of Lisbon since the adoption of the Commission proposal, article 168(4) of the Treaty on the Functioning of the European Union is added as legal basis to the amended proposal. Moreover, this amended proposal further reinforces the rights of patients. In particular, the marketing authorisation holders will have the obligation , and no longer the possibility, to make available certain information, such as the labelling and the package leaflet. The amendments introduced by the Commission in light of the European Parliament’s amendments aim to : recall that in the Commission Communication concerning the " Report on current practices with regard to the provision of information to patients on medicinal products " the need for a more precise distinction between advertising and information was highlighted ; specify that the new Title introduced in Directive 2001/83/EC is intended to place emphasis on the rights and interests of patients; specify that although the pre-control of information is performed by the Agency for centrally approved medicinal products, the monitoring of the information rests with Member States. It is appropriate to ensure consistently that the Agency is also responsible for the control of the information made available through Internet websites registered in the Member States. Specific provisions are introduced to clarify the operation of this control mechanism in such case of information made available through Internet websites registered with the Member States; provide for the procedure regarding cases when the Agency requests for changes within the information submitted for control and for the fees applicable which should be proportionate to the additional work. Considering that the normal delay is 60 days, the subsequent delay should be of 30 days; provide that the EudraPharm database should be available in all EU languages . Such a change has been introduced as regards the lay-out of the database; on the other hand, the information contained in the database will be available in the languages of Member States where the medicinal product is authorised; provide that EudraPharm should be actively promoted to European citizens . This should be done through the development of the European medicines web-portal established by Regulation (EU) No 1235/2010 as the central point of access to information about medicinal products. The proposal has no implication for the budget of the Union. For legal clarity and in order to facilitate the ordinary legislative procedure, this text replaces COM(2011) 632 final , presented on 11/10/2011, which is consequently withdrawn.
          • date: 2014-05-21T00:00:00 type: Proposal withdrawn by Commission body: EC summary: As announced in Official Journal C 153 of 21 May 2014, the Commission decided to withdraw this proposal, which had become obsolete.
          other
          • body: CSL type: Council Meeting council: Former Council configuration
          • body: EC dg: url: http://ec.europa.eu/dgs/health_consumer/index_en.htm title: Health and Consumers commissioner: BORG Tonio
          otherinst
          • name: European Economic and Social Committee
          • name: European Committee of the Regions
          procedure/Mandatory consultation of other institutions
          Economic and Social Committee Committee of the Regions
          procedure/Modified legal basis
          Old
          Rules of Procedure of the European Parliament EP 150
          New
          Rules of Procedure EP 150
          procedure/dossier_of_the_committee
          Old
          ENVI/7/00156;ENVI/7/09017
          New
          • ENVI/7/00156
          • ENVI/7/09017
          procedure/other_consulted_institutions
          European Economic and Social Committee European Committee of the Regions
          procedure/subject
          Old
          • 4.20.04 Pharmaceutical products and industry
          • 4.60.02 Consumer information, advertising, labelling
          New
          4.20.04
          Pharmaceutical products and industry
          4.60.02
          Consumer information, advertising, labelling
          activities/10/docs/0/url
          Old
          http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2011/0632/COM_COM(2011)0632_EN.pdf
          New
          http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2011/0632/COM_COM(2011)0632_EN.pdf
          activities/11/docs/0/url
          Old
          http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=2012&nu_doc=49
          New
          http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2012/0049/COM_COM(2012)0049(COR1)_EN.pdf
          links/European Commission/title
          Old
          PreLex
          New
          EUR-Lex
          activities
          • date: 2008-12-10T00:00:00 docs: url: http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2008/0662/COM_COM(2008)0662_EN.pdf celexid: CELEX:52008PC0662:EN type: Legislative proposal published title: COM(2008)0662 type: Legislative proposal published body: EC commission: DG: url: http://ec.europa.eu/dgs/health_consumer/index_en.htm title: Health and Consumers Commissioner: BORG Tonio
          • date: 2009-01-13T00:00:00 body: EP type: Committee referral announced in Parliament, 1st reading/single reading committees: body: EP shadows: group: PPE name: ROSSI Oreste group: S&D name: PARGNEAUX Gilles group: ALDE name: PARVANOVA Antonyia group: Verts/ALE name: SCHLYTER Carl group: ECR name: CABRNOCH Milan group: GUE/NGL name: MAŠTÁLKA Jiří responsible: True committee: ENVI date: 2012-03-01T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: PPE name: FJELLNER Christofer body: EP responsible: True committee: ENVI date: 2009-07-21T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: PPE name: FJELLNER Christofer body: EP responsible: True committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP responsible: False committee_full: Internal Market and Consumer Protection committee: IMCO body: EP responsible: False committee: IMCO date: 2009-09-14T00:00:00 committee_full: Internal Market and Consumer Protection rapporteur: group: S&D name: CORREIA DE CAMPOS António Fernando body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE body: EP responsible: False committee: ITRE date: 2009-09-16T00:00:00 committee_full: Industry, Research and Energy rapporteur: group: ALDE name: CHATZIMARKAKIS Jorgo
          • date: 2009-10-19T00:00:00 body: EP type: Committee referral announced in Parliament, 1st reading/single reading committees: body: EP shadows: group: PPE name: ROSSI Oreste group: S&D name: PARGNEAUX Gilles group: ALDE name: PARVANOVA Antonyia group: Verts/ALE name: SCHLYTER Carl group: ECR name: CABRNOCH Milan group: GUE/NGL name: MAŠTÁLKA Jiří responsible: True committee: ENVI date: 2012-03-01T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: PPE name: FJELLNER Christofer body: EP responsible: True committee: ENVI date: 2009-07-21T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: PPE name: FJELLNER Christofer body: EP responsible: True committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP responsible: False committee_full: Internal Market and Consumer Protection committee: IMCO body: EP responsible: False committee: IMCO date: 2009-09-14T00:00:00 committee_full: Internal Market and Consumer Protection rapporteur: group: S&D name: CORREIA DE CAMPOS António Fernando body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE body: EP responsible: False committee: ITRE date: 2009-09-16T00:00:00 committee_full: Industry, Research and Energy rapporteur: group: ALDE name: CHATZIMARKAKIS Jorgo
          • body: CSL meeting_id: 2980 docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=2980*&MEET_DATE=30/11/2009 type: Debate in Council title: 2980 council: Employment, Social Policy, Health and Consumer Affairs date: 2009-11-30T00:00:00 type: Council Meeting
          • date: 2010-09-28T00:00:00 body: EP committees: body: EP shadows: group: PPE name: ROSSI Oreste group: S&D name: PARGNEAUX Gilles group: ALDE name: PARVANOVA Antonyia group: Verts/ALE name: SCHLYTER Carl group: ECR name: CABRNOCH Milan group: GUE/NGL name: MAŠTÁLKA Jiří responsible: True committee: ENVI date: 2012-03-01T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: PPE name: FJELLNER Christofer body: EP responsible: True committee: ENVI date: 2009-07-21T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: PPE name: FJELLNER Christofer body: EP responsible: True committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP responsible: False committee_full: Internal Market and Consumer Protection committee: IMCO body: EP responsible: False committee: IMCO date: 2009-09-14T00:00:00 committee_full: Internal Market and Consumer Protection rapporteur: group: S&D name: CORREIA DE CAMPOS António Fernando body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE body: EP responsible: False committee: ITRE date: 2009-09-16T00:00:00 committee_full: Industry, Research and Energy rapporteur: group: ALDE name: CHATZIMARKAKIS Jorgo type: Vote in committee, 1st reading/single reading
          • date: 2010-10-19T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A7-2010-289&language=EN type: Committee report tabled for plenary, 1st reading/single reading title: A7-0289/2010 body: EP committees: body: EP shadows: group: PPE name: ROSSI Oreste group: S&D name: PARGNEAUX Gilles group: ALDE name: PARVANOVA Antonyia group: Verts/ALE name: SCHLYTER Carl group: ECR name: CABRNOCH Milan group: GUE/NGL name: MAŠTÁLKA Jiří responsible: True committee: ENVI date: 2012-03-01T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: PPE name: FJELLNER Christofer body: EP responsible: True committee: ENVI date: 2009-07-21T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: PPE name: FJELLNER Christofer body: EP responsible: True committee_full: Environment, Public Health and Food Safety committee: ENVI body: EP responsible: False committee_full: Internal Market and Consumer Protection committee: IMCO body: EP responsible: False committee: IMCO date: 2009-09-14T00:00:00 committee_full: Internal Market and Consumer Protection rapporteur: group: S&D name: CORREIA DE CAMPOS António Fernando body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE body: EP responsible: False committee: ITRE date: 2009-09-16T00:00:00 committee_full: Industry, Research and Energy rapporteur: group: ALDE name: CHATZIMARKAKIS Jorgo type: Committee report tabled for plenary, 1st reading/single reading
          • date: 2010-11-22T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?secondRef=TOC&language=EN&reference=20101122&type=CRE type: Debate in Parliament title: Debate in Parliament body: EP type: Debate in Parliament
          • date: 2010-11-24T00:00:00 docs: url: http://www.europarl.europa.eu/oeil/popups/sda.do?id=18958&l=en type: Results of vote in Parliament title: Results of vote in Parliament url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P7-TA-2010-430 type: Decision by Parliament, 1st reading/single reading title: T7-0430/2010 body: EP type: Results of vote in Parliament
          • body: CSL meeting_id: 3053 docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=3053*&MEET_DATE=06/12/2010 type: Debate in Council title: 3053 council: Employment, Social Policy, Health and Consumer Affairs date: 2010-12-06T00:00:00 type: Council Meeting
          • body: CSL meeting_id: 3095 docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=3095*&MEET_DATE=30/05/2011 type: Debate in Council title: 3095 council: Employment, Social Policy, Health and Consumer Affairs date: 2011-05-30T00:00:00 type: Council Meeting
          • date: 2011-10-11T00:00:00 docs: url: http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2011/0632/COM_COM(2011)0632_EN.pdf celexid: CELEX:52011PC0632:EN type: Modified legislative proposal published title: COM(2011)0632 type: Modified legislative proposal published body: EC commission: DG: url: http://ec.europa.eu/dgs/health_consumer/index_en.htm title: Health and Consumers Commissioner: BORG Tonio
          • date: 2012-02-10T00:00:00 docs: url: http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=2012&nu_doc=49 celexid: CELEX:52012PC0049:EN type: Amended legislative proposal for reconsultation published title: COM(2012)0049 type: Amended legislative proposal for reconsultation published body: EC commission: DG: url: http://ec.europa.eu/dgs/health_consumer/index_en.htm title: Health and Consumers Commissioner: BORG Tonio
          • date: 2012-02-10T00:00:00 body: EP/CSL type: Formal reconsultation of Parliament
          • date: 2014-05-21T00:00:00 type: Proposal withdrawn by Commission body: EC commission: DG: url: http://ec.europa.eu/dgs/health_consumer/index_en.htm title: Health and Consumers Commissioner: BORG Tonio
          committees
          • body: EP shadows: group: PPE name: ROSSI Oreste group: S&D name: PARGNEAUX Gilles group: ALDE name: PARVANOVA Antonyia group: Verts/ALE name: SCHLYTER Carl group: ECR name: CABRNOCH Milan group: GUE/NGL name: MAŠTÁLKA Jiří responsible: True committee: ENVI date: 2012-03-01T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: PPE name: FJELLNER Christofer
          • body: EP responsible: True committee: ENVI date: 2009-07-21T00:00:00 committee_full: Environment, Public Health and Food Safety rapporteur: group: PPE name: FJELLNER Christofer
          • body: EP responsible: True committee_full: Environment, Public Health and Food Safety committee: ENVI
          • body: EP responsible: False committee_full: Internal Market and Consumer Protection committee: IMCO
          • body: EP responsible: False committee: IMCO date: 2009-09-14T00:00:00 committee_full: Internal Market and Consumer Protection rapporteur: group: S&D name: CORREIA DE CAMPOS António Fernando
          • body: EP responsible: False committee_full: Industry, Research and Energy committee: ITRE
          • body: EP responsible: False committee: ITRE date: 2009-09-16T00:00:00 committee_full: Industry, Research and Energy rapporteur: group: ALDE name: CHATZIMARKAKIS Jorgo
          links
          National parliaments
          European Commission
          other
          • body: CSL type: Council Meeting council: Former Council configuration
          • body: EC dg: url: http://ec.europa.eu/dgs/health_consumer/index_en.htm title: Health and Consumers commissioner: BORG Tonio
          procedure
          dossier_of_the_committee
          ENVI/7/00156;ENVI/7/09017
          Mandatory consultation of other institutions
          Economic and Social Committee Committee of the Regions
          reference
          2008/0255(COD)
          instrument
          Regulation
          legal_basis
          stage_reached
          Procedure lapsed or withdrawn
          subtype
          Legislation
          Modified legal basis
          Rules of Procedure of the European Parliament EP 150
          title
          Medicinal products for human use: information on products subject to medical prescription
          type
          COD - Ordinary legislative procedure (ex-codecision procedure)
          subject